Connectivity- vs Scalp-Based Targeting of Accelerated Transcranial Magnetic Stimulation for Depression

Does individualized, connectivity-based targeting improve treatment-resistant depression more than scalp-based targeting for high-dose accelerated transcranial magnetic stimulation (aTMS)?In this randomized clinical trial, 40 adults with treatment-resistant depression showed significantly larger antidepressant benefits with connectivity- vs scalp-based targeting of aTMS. Connectivity-based targeting of a previously defined convergent depression circuit had a large effect size, with a number needed to scan of 5 individuals, and connectivity-based targets were reproducible within individuals and different between individuals.The findings suggest that individualized, connectivity-based targeting of the convergent depression circuit in high-dose aTMS should be considered for individuals with treatment-resistant depression.

Corresponding Author: Joseph J. Taylor, MD, PhD, Center for Brain Circuit Therapeutics, Brigham and Women’s Hospital, 60 Fenwood Rd, Boston, MA 02115 (jtaylor61@bwh.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.